INHIBITION OF PROSTATE CANCER CELL LINE (PC-3) BY ANHYDRODIHYDROARTEMISININ (ADHA) THROUGH CASPASE-DEPENDENT PATHWAY

被引：5

作者：

Ahmad, Faiz ^{[1
]}

Sarder, Amit ^{[1
]}

Gour, Rajesh ^{[2
]}

Karna, Shibendra Kumar Lal ^{[1
]}

Arora, Priya ^{[1
]}

Kartha, K. P. Ravindranathan ^{[2
]}

Pokharel, Yuba Raj ^{[1
]}

机构：

[1] South Asian Univ, Fac Life Sci & Biotechnol, New Delhi 110021, India

[2] Natl Inst Pharmaceut Educ & Res, Dept Med Chem, Sas Nagar 160062, Punjab, India

来源：

EXCLI JOURNAL | 2020年 / 19卷

关键词：

Anhydrodihydroartemisinin; PC-3; apoptosis; caspase; 3; 7; c-Jun; Akt; NF-kappa B; ARTEMISIA-ANNUA; ANTIMALARIAL; DERIVATIVES;

D O I：

10.17179/excli2020-1331

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Cancer is a generic term for a large group of diseases characterized by the growth of abnormal cells, which is the second leading cause of death globally. To treat cancer, currently, a number of anticancer drugs belonging to various classes chemically are available. The discovery of artemisinin and its derivatives such as artesunate, arteether, and artemether became a milestone in the cure for malaria. Here, we report the anti-cancer property of anhydrodihydroartemisinin (ADHA) - a semisynthetic derivative of artemisinin against prostate cancer cell line PC-3. ADHA was found to be inhibiting growth of PC-3 cells. ADHA was also found to be inhibiting migration of PC-3 cells. At molecular level, ADHA was found to be inhibiting the expression of c-Jun, p-c-Jun, p-Akt and NF-kappa B and activated caspase 3 and 7. The results show that ADHA like few other artemisinin derivatives hold potential to be used as an anti-cancer agent against prostate cancer cells.

引用

页码：613 / 619

页数：7

共 27 条

[11] Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer [J].

Ju, Rui-Jun ;

Cheng, Lan ;

Peng, Xiao-Ming ;

Wang, Teng ;

Li, Cui-Qing ;

Song, Xiao-Li ;

Liu, Shuang ;

Chao, Jian-Ping ;

Li, Xue-Tao .

ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2018, 46 :S616-S628

[12] MICROBIAL AND MAMMALIAN METABOLISM STUDIES OF THE SEMISYNTHETIC ANTIMALARIAL, ANHYDRODIHYDROARTEMISININ [J].

KHALIFA, SI ;

BAKER, JK ;

ROGERS, RD ;

ELFERALY, FS ;

HUFFORD, CD .

PHARMACEUTICAL RESEARCH, 1994, 11 (07) :990-994

[13] AKT Kinase Pathway: A Leading Target in Cancer Research [J].

Kumar, Ambuj ;

Rajendran, Vidya ;

Sethumadhavan, Rao ;

Purohit, Rituraj .

SCIENTIFIC WORLD JOURNAL, 2013,

[14] Development of artemisinin compounds for cancer treatment [J].

Lai, Henry C. ;

Singh, Narendra P. ;

Sasaki, Tomikazu .

INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) :230-246

[15] Biological Actions of Artemisinin: Insights from Medicinal Chemistry Studies [J].

Li, Jian ;

Zhou, Bing .

MOLECULES, 2010, 15 (03) :1378-1397

[16] The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy [J].

Lukey, Michael J. ;

Greene, Kai Su ;

Erickson, Jon W. ;

Wilson, Kristin F. ;

Cerione, Richard A. .

NATURE COMMUNICATIONS, 2016, 7

[17] Artemisinin and the antimalarial endoperoxides: From herbal remedy to targeted chemotherapy [J].

Meshnick, SR ;

Taylor, TE ;

Kamchonwongpaisan, S .

MICROBIOLOGICAL REVIEWS, 1996, 60 (02) :301-+

[18] DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation [J].

Mialon, A ;

Sankinen, M ;

Söderström, H ;

Junttila, TT ;

Holmström, T ;

Koivusalo, R ;

Papageorgiou, AC ;

Johnson, RS ;

Hietanen, S ;

Elenius, K ;

Westermarck, J .

MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (12) :5040-5051

[19] Roles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic Approaches [J].

Park, Mi Hee ;

Hong, Jin Tae .

CELLS, 2016, 5 (02)

[20]

Sarder A., 2016, Int. J. Med. Biomed. Sci, V1, P12, DOI [10.55530/ijmbiosnepal.v1i3.19, DOI 10.55530/IJMBIOSNEPAL.V1I3.19]

← 1 2 3 →